Nifty
Sensex
:
:
11928.45
39747.28
84.35 (0.71%)
312.56 (0.79%)

Pharmaceuticals & Drugs

Rating :
56/99  (View)

BSE: 532321 | NSE: CADILAHC

254.75
1.95 (0.77%)
27-May-2019 | 12:54PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  254.60
  •  259.75
  •  253.00
  •  252.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2019045
  •  5143.52
  •  432.50
  •  241.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 25,880.21
  • 13.07
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 29,972.01
  • 1.38%
  • 2.75

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.79%
  • 1.29%
  • 5.62%
  • FII
  • DII
  • Others
  • 3.75%
  • 5.44%
  • 9.11%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.06
  • 10.51
  • 8.09

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.11
  • 18.85
  • 3.96

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.24
  • 16.34
  • -3.24

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.30
  • 26.82
  • 25.32

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.12
  • 6.32
  • 5.53

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.52
  • 18.48
  • 18.03

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Net Sales
3,577.90
3,259.90
9.75%
2,961.20
3,221.90
-8.09%
2,893.70
2,234.80
29.48%
3,250.20
2,513.30
29.32%
Expenses
2,738.00
2,401.30
14.02%
2,273.40
2,364.80
-3.87%
2,248.70
1,958.10
14.84%
2,379.80
2,048.80
16.16%
EBITDA
839.90
858.60
-2.18%
687.80
857.10
-19.75%
645.00
276.70
133.10%
870.40
464.50
87.38%
EBIDTM
23.47%
26.34%
23.23%
26.60%
22.29%
12.38%
26.78%
18.48%
Other Income
31.00
25.70
20.62%
30.40
22.50
35.11%
101.30
21.00
382.38%
28.70
73.10
-60.74%
Interest
45.50
13.40
239.55%
35.70
40.50
-11.85%
35.00
21.80
60.55%
15.40
9.80
57.14%
Depreciation
153.70
146.90
4.63%
147.50
126.30
16.79%
141.80
121.60
16.61%
144.00
114.10
26.21%
PBT
671.70
724.00
-7.22%
535.00
712.80
-24.94%
569.50
154.30
269.09%
739.70
413.70
78.80%
Tax
158.60
178.60
-11.20%
124.70
212.30
-41.26%
120.30
29.30
310.58%
144.20
1.90
7,489.47%
PAT
513.10
545.40
-5.92%
410.30
500.50
-18.02%
449.20
125.00
259.36%
595.50
411.80
44.61%
PATM
14.34%
16.73%
13.86%
15.53%
15.52%
5.59%
18.32%
16.38%
EPS
4.99
5.31
-6.03%
4.08
4.92
-17.07%
4.50
1.35
233.33%
5.77
3.76
53.46%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
12,683.00
11,904.90
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
5,263.30
4,630.60
3,686.80
2,927.50
Net Sales Growth
12.94%
26.97%
-0.53%
8.96%
19.76%
13.63%
20.79%
13.66%
25.60%
25.94%
 
Cost Of Goods Sold
4,414.00
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
1,464.10
1,286.20
1,011.20
839.40
Gross Profit
8,269.00
8,248.00
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
3,799.20
3,344.40
2,675.60
2,088.10
GP Margin
65.20%
69.28%
67.31%
71.64%
67.47%
66.60%
67.96%
72.18%
72.22%
72.57%
71.33%
Total Expenditure
9,639.90
9,076.30
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
4,181.50
3,614.10
2,878.20
2,344.40
Power & Fuel Cost
-
226.30
174.50
168.80
145.40
129.70
124.40
93.40
78.90
66.00
49.90
% Of Sales
-
1.90%
1.86%
1.79%
1.68%
1.80%
1.96%
1.77%
1.70%
1.79%
1.70%
Employee Cost
-
1,820.30
1,485.20
1,261.60
1,096.50
974.00
818.40
679.90
584.00
401.10
310.90
% Of Sales
-
15.29%
15.84%
13.38%
12.67%
13.48%
12.87%
12.92%
12.61%
10.88%
10.62%
Manufacturing Exp.
-
1,197.50
955.30
1,019.60
1,136.90
936.50
897.30
718.90
553.40
429.10
345.20
% Of Sales
-
10.06%
10.19%
10.82%
13.14%
12.96%
14.11%
13.66%
11.95%
11.64%
11.79%
General & Admin Exp.
-
509.50
466.00
432.70
326.80
365.70
342.20
271.90
234.90
218.50
172.20
% Of Sales
-
4.28%
4.97%
4.59%
3.78%
5.06%
5.38%
5.17%
5.07%
5.93%
5.88%
Selling & Distn. Exp.
-
1,014.50
826.40
979.60
960.30
902.40
857.50
767.40
710.70
585.30
477.70
% Of Sales
-
8.52%
8.81%
10.39%
11.10%
12.49%
13.49%
14.58%
15.35%
15.88%
16.32%
Miscellaneous Exp.
-
651.30
502.60
561.80
417.40
310.30
157.40
185.90
166.00
167.00
477.70
% Of Sales
-
5.47%
5.36%
5.96%
4.82%
4.30%
2.48%
3.53%
3.58%
4.53%
5.09%
EBITDA
3,043.10
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
1,081.80
1,016.50
808.60
583.10
EBITDA Margin
23.99%
23.76%
20.28%
24.71%
20.27%
16.51%
17.67%
20.55%
21.95%
21.93%
19.92%
Other Income
191.40
133.00
147.10
116.60
57.20
58.00
38.40
53.00
22.80
15.90
20.40
Interest
131.60
110.80
63.10
52.80
67.90
90.20
168.70
182.70
69.90
82.10
97.80
Depreciation
587.00
538.80
373.30
292.10
287.30
201.20
184.70
157.90
126.90
133.90
111.80
PBT
2,515.90
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
794.20
842.50
608.50
393.90
Tax
547.80
564.40
128.90
177.40
259.40
106.00
118.80
113.00
106.40
74.10
66.60
Tax Rate
21.77%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
14.23%
12.63%
12.27%
18.01%
PAT
1,968.10
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
652.60
711.00
506.00
294.90
PAT before Minority Interest
1,931.50
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
681.20
736.10
529.80
303.20
Minority Interest
-36.60
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
-28.60
-25.10
-23.80
-8.30
PAT Margin
15.52%
14.39%
15.51%
20.06%
13.28%
11.12%
10.28%
12.40%
15.35%
13.72%
10.07%
PAT Growth
24.35%
17.82%
-23.11%
64.64%
42.92%
22.97%
0.14%
-8.21%
40.51%
71.58%
 
Unadjusted EPS
19.34
17.35
14.53
19.19
11.24
39.25
31.92
31.87
34.73
24.67
22.20

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
2,585.90
2,171.50
1,628.50
1,235.20
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
68.20
68.20
Total Reserves
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
2,483.50
2,069.10
1,560.30
1,167.00
Non-Current Liabilities
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
1,555.10
956.30
1,204.60
1,398.90
Secured Loans
200.60
319.60
393.80
664.00
851.40
917.20
901.90
670.90
978.20
1,068.40
Unsecured Loans
2,354.50
2,148.80
502.60
486.40
510.80
508.80
420.40
92.00
112.30
198.90
Long Term Provisions
155.90
151.20
120.70
90.40
76.10
66.50
75.60
61.90
0.00
0.00
Current Liabilities
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
2,191.60
1,415.90
871.10
691.60
Trade Payables
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
545.50
570.60
619.60
525.60
Other Current Liabilities
1,484.90
1,212.10
860.70
628.20
708.10
509.20
730.90
367.30
56.40
47.40
Short Term Borrowings
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
687.10
259.80
0.00
0.00
Short Term Provisions
152.20
68.90
81.30
382.50
292.70
247.30
228.10
218.20
195.10
118.60
Total Liabilities
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
3,743.40
3,348.50
Net Block
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
2,857.10
1,832.60
1,684.40
1,529.80
Gross Block
9,338.50
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
3,990.90
2,801.70
2,557.80
2,287.00
Accumulated Depreciation
2,842.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
1,096.00
929.90
835.00
719.90
Non Current Assets
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
3,610.00
2,485.30
1,953.30
1,743.60
Capital Work in Progress
1,527.20
1,543.30
950.80
797.90
891.50
735.60
483.90
431.00
211.10
155.50
Non Current Investment
470.90
385.70
217.10
33.20
22.20
21.20
21.20
20.70
20.70
24.90
Long Term Loans & Adv.
300.00
384.70
661.20
637.10
511.10
400.10
247.80
201.00
0.00
0.00
Other Non Current Assets
130.30
234.10
174.70
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
2,813.00
2,125.30
1,779.90
1,561.10
Current Investments
274.80
49.10
199.10
121.20
64.40
93.30
3.00
0.00
0.00
0.00
Inventories
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
1,090.50
811.90
750.40
601.20
Sundry Debtors
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
920.90
765.20
466.80
454.90
Cash & Bank
1,314.90
1,543.50
638.70
669.90
548.80
583.80
466.60
295.20
250.70
251.70
Other Current Assets
1,048.40
80.00
124.10
70.70
323.50
345.90
332.00
253.00
312.00
253.30
Short Term Loans & Adv.
730.10
268.50
234.80
240.80
254.90
279.00
274.60
206.20
308.00
251.40
Net Current Assets
2,146.70
716.50
819.40
941.60
623.90
521.30
621.40
709.40
908.80
869.50
Total Assets
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
3,743.40
3,348.50

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
919.30
1,311.70
1,893.50
993.60
902.80
603.40
511.10
682.60
695.40
218.60
PBT
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
794.20
842.50
603.90
369.80
Adjustment
624.30
333.70
249.80
344.50
269.00
315.90
320.90
208.40
228.10
200.30
Changes in Working Capital
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
-421.70
-175.30
-123.60
-121.00
Cash after chg. in Working capital
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
693.40
875.60
708.40
449.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-620.60
-237.60
-646.00
-386.90
-172.80
-272.00
-143.50
-152.50
-77.10
-48.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
-12.50
14.90
-80.70
-32.50
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
-1,199.50
-466.00
-371.60
-409.50
Net Fixed Assets
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
-361.70
-266.60
-223.80
-138.40
Net Investments
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
-513.40
-99.90
-3.50
-152.70
Others
-679.10
-708.30
-223.60
458.20
79.30
32.30
-324.40
-99.50
-144.30
-118.40
Cash from Financing Activity
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
859.80
-172.10
-324.80
349.60
Net Cash Inflow / Outflow
-2.90
755.60
95.20
177.80
-63.90
206.90
171.40
44.50
-1.00
158.70
Opening Cash & Equivalents
1,592.60
837.00
737.90
612.60
676.50
469.60
295.20
250.70
251.70
92.60
Closing Cash & Equivalent
1,589.70
1,592.60
837.00
790.40
612.60
676.50
466.60
295.20
250.70
251.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
85.40
67.97
55.66
41.52
33.58
28.75
25.25
21.21
15.82
11.65
ROA
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
12.35%
17.62%
14.94%
10.28%
ROE
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
28.64%
38.85%
37.71%
26.91%
ROCE
18.41%
16.50%
28.60%
23.21%
17.20%
18.21%
24.01%
30.56%
26.55%
21.46%
Fixed Asset Turnover
1.37
1.38
1.76
1.80
1.63
1.55
1.58
1.75
1.54
1.42
Receivable days
83.84
76.72
63.29
56.38
51.71
52.78
57.47
47.97
45.13
49.59
Inventory Days
64.05
59.88
54.52
60.13
63.89
64.82
64.85
60.83
66.19
65.73
Payable days
71.22
74.18
67.53
55.78
50.51
43.54
49.87
64.40
75.83
73.08
Cash Conversion Cycle
76.67
62.42
50.28
60.73
65.09
74.05
72.45
44.40
35.49
42.24
Total Debt/Equity
0.62
0.75
0.43
0.62
0.79
0.99
0.89
0.50
0.67
1.06
Interest Cover
21.87
26.55
40.75
22.29
11.45
5.79
5.35
13.05
8.36
4.78

News Update


  • Zydus Cadila gets USFDA’s nod for Esomeprazole Magnesium Delayed-Release Capsules
    23rd May 2019, 11:03 AM

    It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Cadila Healthcare’s US arm among generic companies facing lawsuit by US states
    15th May 2019, 12:11 PM

    In Cadila Healthcare’s opinion this particular matter is not likely to have any material impact on the operations and financials of the company

    Read More
  • Zydus Cadila receives USFDA’s final approval for Chlorthalidone Tablets
    13th May 2019, 11:05 AM

    It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila’s arm recalls 7,668 bottles of Carvedilol Tablets from American market
    6th May 2019, 10:00 AM

    The drug firm is recalling the drug due to the ‘presence of foreign tablets/ capsules’

    Read More
  • USFDA concludes inspection at Cadila Healthcare’s manufacturing facility in Ahmedabad
    3rd May 2019, 16:06 PM

    The inspection was conducted from April 22, 2019 to May 3, 2019

    Read More
  • Zydus Cadila gets USFDA’s nod for Bosentan Tablets, Trientine Hydrochloride Capsules
    30th Apr 2019, 12:25 PM

    Both the products will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila, SIFI tie up to launch innovative intraocular lenses in India
    30th Apr 2019, 10:54 AM

    Zydus Cadila and SIFI look forward to bringing such innovations to India and to the entire South Asia region

    Read More
  • Zydus Cadila receives USFDA’s approval for Leflunomide Tablets
    25th Apr 2019, 14:07 PM

    This medication is used to treat rheumatoid arthritis, a condition affecting multiple small and large joints of the body

    Read More
  • Zydus Cadila receives approval from USFDA for Acetazolamide for Injection
    17th Apr 2019, 14:20 PM

    It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad

    Read More
  • Zydus Cadila starts phase 3 trial of Desidustat
    17th Apr 2019, 12:57 PM

    This Phase III study will be a multicenter (50- 60 sites), randomized, active-controlled clinical trial

    Read More
  • Zydus Cadila receives tentative approval from USFDA for Lacosamide Tablets
    8th Apr 2019, 12:05 PM

    Lacosamide is an anticonvulsant or antiepileptic drug, used to prevent and control seizures

    Read More
  • Zydus Cadila receives USFDA’s approval for Tofacitinib Tablets
    6th Apr 2019, 15:41 PM

    Tofacitinib is used alone or with other medications to treat moderate to severe forms of rheumatoid arthritis

    Read More
  • USFDA concludes inspection at Cadila Healthcare’s manufacturing facility in Ahmedabad
    3rd Apr 2019, 14:57 PM

    The inspection was conducted from March 25, 2019 to April 02, 2019

    Read More
  • Zydus Cadila receives USFDA’s approval for Mirabegron Extended-Release Tablets
    2nd Apr 2019, 11:56 AM

    Mirabegron is selective beta 3-adrenoceptor agonist approved for the treatment of Overactive Bladder

    Read More
  • Zydus Cadila gets USFDA’s nod for Ambrisentan Tablets
    29th Mar 2019, 11:10 AM

    The US sales of Ambrisentan Tablets USP stood at $943 million in 2018

    Read More
  • Cadila Healthcare’s arm gets one observation for Ahmedabad plant from USFDA
    27th Mar 2019, 14:20 PM

    USFDA has conducted a Pre-Approval Inspection for Doxorubicin Liposomal, a complex oncological injectable at Alidac Pharmaceuticals

    Read More
  • Zydus Cadila launches Tadalafil Tablets
    27th Mar 2019, 14:17 PM

    The group now has 257 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • USFDA inspects Cadila Healthcare’s Pharmaceutical Technology Centre at Ahmedabad
    22nd Mar 2019, 14:47 PM

    At the end of the inspection, no observations have been issued

    Read More
  • Zydus Cadila receives approval from USFDA for Lurasidone Hydrochloride Tablets
    22nd Mar 2019, 14:30 PM

    The medication is used to treat certain mental/mood disorders such as schizophrenia, depression associated with bipolar disorder

    Read More
  • Zydus Cadila receives final approval from USFDA for Acyclovir Ointment
    19th Mar 2019, 12:51 PM

    Acyclovir is an antiviral drug which stops the growth of certain viruses

    Read More
  • Zydus Cadila gets USFDA’s nod for Valsartan and Hydrochlorothiazide Tablets
    16th Mar 2019, 15:15 PM

    The drug is used to treat high blood pressure

    Read More
  • Zydus Cadila gets tentative nod for Sitagliptin, Metformin Hydrochloride Tablets
    14th Mar 2019, 14:04 PM

    It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets USFDA’s nod for Potassium Chloride Extended-Release Capsules
    13th Mar 2019, 12:05 PM

    This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood

    Read More
  • Zydus Cadila receives final USFDA’s nod for Atenolol and Chlorthalidone Tablets
    12th Mar 2019, 11:55 AM

    The group now has 253 approvals and has so far filed over 330 ANDAS since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Cadila receives USFDA’s nod for Rivastigmine Transdermal System
    5th Mar 2019, 14:02 PM

    The group also received the final approval for Rosuvastatin Tablets

    Read More
  • Zydus Cadila receives nod from the USFDA for Phytonadione, Colchicine Tablets
    21st Feb 2019, 14:23 PM

    The products will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.